Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07254715

Effect of Itopride on Semaglutide Gastroparesis

Does Itopride Improve Semaglutide Induced Gastroparesis Ultrasound Before Anesthesia? Randomized Controlled Trial

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Ain Shams University · Academic / Other
Sex
Female
Age
40 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Semaglutide delays gastric emptying and increases the risk of aspiration with anesthesia; So, the addition of prokinetics as Itopride, could enhance gastric emptying and hasten surgery. The investigator will evaluate the effect of Itopride on Semaglutide-induced gastroparesis and residual gastric contents after 8 hours of fasting by gastric ultrasound before anesthesia.

Detailed description

Semaglutide delays gastric emptying and increases the risk of aspiration with anesthesia; So, the addition of prokinetics as Itopride could enhance gastric emptying and hastens surgery. Semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, is gaining popularity for the treatment of type 2 diabetes mellitus (T2DM) and obesity; Semaglutide stimulates insulin excretion and delays gastric emptying.Itopride, a novel prokinetic agent, acts as a dopamine D2 receptor antagonist and an acetylcholine esterase inhibitor. Itopride shows promise in managing gastroparesis symptoms by accelerating gastric emptying, improving gastric tension and sensitivity, and exerting antiemetic effects. The investigator designed this prospective, randomized, double-blind controlled study to evaluate the effect of Itopride on Semaglutide induced gastroparesis and residual gastric contents after 8-hours fasting by gastric ultrasound before anesthesia.

Conditions

Interventions

TypeNameDescription
DRUGItopride HCI 50 mgDaily oral 50mg Itopride tablet TID, 1 hour before meals for 7 days
DRUGPlaceboDaily placebo tablet TID, 1 hour before meals for 7 days

Timeline

Start date
2025-12-01
Primary completion
2026-04-01
Completion
2026-04-01
First posted
2025-11-28
Last updated
2025-11-28

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07254715. Inclusion in this directory is not an endorsement.